Owkin

Owkin is a French-American AI biotechnology company that puts the needs of patients at the forefront of its mission. Many individuals suffer from complex diseases, and the one-size-fits-all approach to treatment often falls short. Patients and their doctors face the challenge of finding the most effective treatment, a process that can be slow and fraught with uncertainty. This is why Owkin was founded: to harness the power of artificial intelligence to understand precisely why a drug will be effective for a specific patient. By doing so, we empower researchers in hospitals, universities, and pharmaceutical companies to accelerate the development of new, safer, and more effective therapies. Our goal is to ensure that every patient receives the right treatment for their individual condition, leading to better outcomes and a higher quality of life.

Our customers, who are leading biopharma companies and academic researchers, are striving to solve some of the most complex problems in medicine. They are often hindered by siloed, difficult-to-access patient data. Owkin addresses this challenge directly with our federated learning technology. This pioneering framework allows our partners to collaborate on research and gain valuable insights from vast, multimodal datasets without ever moving the data from its source, thereby preserving patient privacy and data security. We provide AI-driven solutions, including our AI co-pilot 'K', to identify new drug candidates, de-risk and accelerate clinical trials, and build innovative diagnostic tools. By combining machine learning with deep biological and medical expertise, we help our partners overcome the traditional barriers in drug discovery and development, ultimately bringing new hope and new treatments to patients faster.